Biogen Inc.

Informe acción NasdaqGS:BIIB

Capitalización de mercado: US$28.4b

Salud financiera de hoja de balance de Biogen

Salud financiera controles de criterios 5/6

Biogen tiene un patrimonio de accionistas total de $15.2B y una deuda total de $6.5B, lo que sitúa su ratio deuda-patrimonio en 43%. Sus activos y pasivos totales son $26.6B y $11.4B respectivamente. El BAIT de Biogen es de $2.0B, por lo que su ratio de cobertura de intereses es de 49. Tiene efectivo e inversiones a corto plazo que ascienden a $1.1B.

Información clave

39.6%

Ratio deuda-patrimonio

US$6.29b

Deuda

Ratio de cobertura de intereses19.9x
EfectivoUS$1.91b
PatrimonioUS$15.89b
Total pasivoUS$10.92b
Activos totalesUS$26.80b

Actualizaciones recientes sobre salud financiera

Recent updates

What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Sep 04
What You Can Learn From Biogen Inc.'s (NASDAQ:BIIB) P/E

Biogen: Q2 Earnings, Share Price May Have Bottomed Out As CEO Makes Mark

Aug 17

Biogen Stock: Cheapish, But With Few Growth Prospects

Jul 11

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28
Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Apr 15
The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21
We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Feb 16
Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Feb 14

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Jan 31
Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Biotech And Pharma Diversification Pays Off

Jan 25

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

Dec 26
Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21
An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03
Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16
Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28
Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo ($6.8B) de BIIB superan a sus pasivos a corto plazo ($3.2B).

Pasivo a largo plazo: Los activos a corto plazo ($6.8B) de BIIB no cubren sus pasivos a largo plazo ($8.1B).


Historial y análisis de deuda-patrimonio

Nivel de deuda: El ratio deuda neta-patrimonio (35.9%) de BIIB se considera satisfactorio.

Reducción de la deuda: El ratio deuda-patrimonio de BIIB ha pasado de 43% a 43% en los últimos 5 años.

Cobertura de la deuda: La deuda de BIIB está bien cubierta por el flujo de caja operativo (25.2%).

Cobertura de intereses: Los pagos de intereses de la deuda de BIIB están bien cubiertos por el BAIT (19.9x cobertura).


Hoja de balance


Descubre empresas con salud financiera